



INVESTIGADOR AECC Adjudicatarios

**Dra. María Magdalena Leiva Arjona**

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid

Deciphering the role JNK pathway in cholangiocarcinoma development: molecular basis and cellular networks

Dra. Patricia Muñoz Garrido

Instituto de Investigación Sanitaria Biodonostia, Guipúzcoa

Oncogenic role of miRNA-941 in cholangiocarcinoma metabolism: new potential therapeutic target

Dra. Eva Colas Ortega

Vall d'Hebron Instituto de Recerca (VHIR), Barcelona

PREDITEC: New methods to control recurrence in endometrial cancer

Dra. Laura Martínez Mondragón

Vall d'Hebron Instituto de Recerca (VHIR), Barcelona

Characterization of a new pre-clinical mouse model for angioimmunoblastic T cell lymphoma and development of novel therapeutic strategies

Dra. Alba Llop Guevara

Vall d'Hebron Instituto de Oncología (VHIO), Barcelona

Tumor DNA repair functionality and immunologic profile as predictive and prognostic biomarkers for cancer precision medicine

Dra. María Belén López Millán

Fundación Instituto de Investigación Contra la Leucemia Josep Carreras (IJC), Barcelona

Innovative Therapeutic Strategies for Infant B-cell Acute Lymphoblastic Leukemia: NG2 and CD22 as therapeutic targets

Dr. Joao Miguel Fernandes Alves

Centro De Investigaciones Biomédicas (CINBIO) - Universidad de Vigo, Pontevedra

Genomic heterogeneity of circulating tumor cells as a tool for precision medicine in colorectal cancer

Dr. Jose Luis Orgaz Bueno

Centro de Investigaciones Biológicas (CIB)-CSIC, Madrid

Investigating the regulation of Myosin II in melanoma progression and during adaptation and resistance to targeted therapies

Dra. Valentine Comaills

Centro Andaluz de Biología Molecular y Medicina regenerativa (CABIMER) , Sevilla

Origin of genomic instability: Understanding the biological influence of inflammation in the initiation of pancreatic tumorigenesis



INVESTIGADOR AECC Suplentes



Dra. Caroline Nunes Xavier

Instituto de Investigación Sanitaria Biocruces,
Vizcaya

Nuevos puntos de control inmunitario como
dianas terapéuticas en cáncer de riñón

Dra. Itziar Otano

Centro de Estudios, Investigación y Medicina del
Deporte (CEIMD), Navarra

Use of bi-specific antibodies to boost adoptive
transfer of T cell receptor-transgenic T cells

Dr. Johanne Le Cog

Centro de Investigaciones Biológicas-CSIC,
Madrid

SH2-containing Inositol 5'-Phosphatase: From
new mechanistic insights to future cancer drugs

Dr. Daniel Gómez Cabello

Instituto de Biomédicina de Sevilla (IBIS), Sevilla

Nuevas perspectivas del mantenimiento de la integridad
del genoma bajo estrés en el ADN ribosómico en
células tumorales

Dr. Tian Tian

Vall d'Hebron Instituto de Oncología (VHIO), Barcelona

Characterization of fusion protein BRD-NUT in NUT
midline carcinoma: from diagnosis to treatment